

What is Claimed is:

1. An oligonucleotide comprising at least 18 nucleotides, wherein the sequence is complementary to an mRNA encoding human integrin-linked kinase.
2. The oligonucleotide according to Claim 1, wherein said sequence is complementary to SEQ ID NO:1.
3. The oligonucleotide according to Claim 2, wherein said sequence is selected from the group consisting of SEQ NO:13 to SEQ ID NO:109.
4. The oligonucleotide according to Claim 3; and a pharmaceutically acceptable carrier.
5. A method of inhibiting expression of integrin linked kinase, the method comprising:  
administering an oligonucleotide composition comprising an oligonucleotide comprising at least 18 nucleotides, wherein the sequence is complementary to an mRNA encoding human integrin linked kinase; and a pharmaceutically acceptable carrier.
6. The method according to Claim 5, wherein said sequence is complementary to SEQ ID NO:1.
7. The method according to Claim 6, wherein said sequence is selected from the group consisting of SEQ NO:13 to SEQ ID NO:109.